What is the half-life of dalbavancin?

Dalbavancin is an antibiotic used primarily to treat certain serious bacterial infections, particularly those caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The half-life of dalbavancin is notably long, which is a key characteristic of this medication.

The pharmacokinetics of dalbavancin show that its half-life is approximately 14 days. This extended half-life allows for infrequent dosing—often less than weekly—which is particularly advantageous in outpatient settings or for patients who may have difficulty adhering to a more frequent dosing schedule. The long duration of action also makes dalbavancin appealing for effectively managing complicated skin and soft tissue infections while providing sustained therapeutic levels in the body.

Understanding the half-life is crucial for determining dosing regimens, potential accumulation in patients with renal impairment, and the duration of therapy necessary to achieve effective concentrations against the pathogens being treated.